<DOC>
	<DOCNO>NCT00942318</DOCNO>
	<brief_summary>A lot insulin-treated type 2 diabetic patient reach adequate glycemic control despite intensive basal-bolus insulin regimen . In case , continuous subcutaneous insulin infusion ( CSII ) , use external pump , could solution improve diabetes control . The aim study compare , one-year period , efficacy CSII ( aspart insulin ) basal-bolus multiple daily injection ( MDI ) treatment ( detemir x 2/d aspart meal ) type 2 diabetic patient , already treat basal-bolus regimen least 6 month , n't reach adequate target glycemic baseline ( HbA1c &gt; 7 -10 % ) .</brief_summary>
	<brief_title>Efficacy Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen Type 2 Diabetes</brief_title>
	<detailed_description>Visit 1 : patient information eligibility criteria assessment Visit 2 : Inform consent signature randomisation ( group CSII MDI ) . Patients randomise CSII group instruct use pump V2 V3 . Visit 3 : 5-day 's hospitalisation . Start CSII MDI treatment . Stop oral diabetic medication except metformin , follow end study . Teaching program diabetes management ( diet , physical activity self-adjustment insulin dos ) . HbA1c , clinical biological parameter . Questionnaires . Follow-up visit 4-7 ( 1 , 3 , 6 , 9 month ) : HbA1c . Treatment adjustment . Adverse event collection . Final visit ( 12 month ) : HbA1c , clinical biological parameter . Questionnaires . Adverse event collection .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 diabetes mellitus Age &gt; 18 year Patients treat least 6 month Multiple daily insulin injection associate long act insulin ( least 1 long act insulin analog injection Glargine Detemir least 2 NPH insulin injection ) plus mealtime rapid act insulin injection ( Human analog ) +/ oral hypoglycemic agent . 7,5 % ≤ HbA1c ≤ 10 % Patients able perform selfmonitoring blood glucose ( SMBG ) measurement insulin injection . SMBG &gt; 3/day Diabetic retinopathy contraindicate glycemic control intensification Situation pathology allow therapeutic education program ( blindness , deafness , low language fluency… ) Situation pathology allow insulin therapy selfmanagement / portable insulin pump use ( rheumatologic pathology , low visual acuity , … ) Recent ( &lt; 3 month ) serious pathology Planned treatment therapy able induce longterm glycemic control worsen Long lasting ( &gt; 2 month ) plan treatment glucocorticoid , octreotide , lanreotide danazol Pregnancy wish ongoing pregnancy Known Haemoglobinopathy . Creatinin clearance &lt; 30ml/min ( MDRD formula ) . Organ transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Continuous subcutaneous insulin infusion</keyword>
	<keyword>Insulin external pump</keyword>
	<keyword>Multiple daily injection</keyword>
	<keyword>Basal-bolus regimen</keyword>
	<keyword>Education</keyword>
</DOC>